Latest news with #TransCon-based
Yahoo
14-04-2025
- Business
- Yahoo
High Growth Tech Stocks In US With Potential For Expansion
The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 20.44% 29.79% ★★★★★★ Arcutis Biotherapeutics 25.76% 58.17% ★★★★★★ TG Therapeutics 26.03% 37.60% ★★★★★★ Alkami Technology 20.46% 85.16% ★★★★★★ Travere Therapeutics 28.65% 65.75% ★★★★★★ Alnylam Pharmaceuticals 22.74% 58.77% ★★★★★★ TKO Group Holdings 22.48% 25.17% ★★★★★★ AVITA Medical 28.22% 55.77% ★★★★★★ Lumentum Holdings 21.61% 120.49% ★★★★★★ Ascendis Pharma 32.36% 59.79% ★★★★★★ Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★★★ Overview: Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference with a market cap of approximately $30.78 billion. Operations: Alnylam generates revenue primarily from the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.25 billion. The company operates within the biotechnology sector with a focus on innovative therapeutic solutions. Alnylam Pharmaceuticals has demonstrated a robust commitment to innovation, particularly through its recent FDA approval of AMVUTTRA for ATTR-CM and Qfitlia for hemophilia. These approvals not only enhance its product portfolio but also underscore its R&D capabilities, reflected in a significant 22.7% annual revenue growth. The company's strategic presentations at various healthcare conferences, coupled with the launch of groundbreaking RNAi therapeutics like vutrisiran, show a clear trajectory towards addressing critical unmet medical needs. Despite being unprofitable currently, Alnylam's projected earnings growth of 58.77% annually suggests potential for future profitability and leadership in the biotech sector. Navigate through the intricacies of Alnylam Pharmaceuticals with our comprehensive health report here. Examine Alnylam Pharmaceuticals' past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★★ Overview: Ascendis Pharma A/S is a biopharmaceutical company specializing in the development of TransCon-based therapies for unmet medical needs across Denmark, Europe, North America, and globally, with a market cap of approximately $9.04 billion. Operations: Ascendis Pharma generates revenue primarily from its biotechnology segment, amounting to €363.64 million. The company is focused on developing TransCon-based therapies to address unmet medical needs across various regions. Ascendis Pharma is navigating a transformative phase with its recent NDA submission for TransCon CNP, targeting achondroplasia treatment, reflecting its commitment to addressing rare diseases through innovative drug development. Despite being unprofitable, the company's revenue is projected to grow at 32.4% annually, outpacing the US market average of 8.3%. With R&D expenses aligning closely with these ambitious projects, Ascendis also announced a share repurchase program valued at $18.25 million, signaling confidence in its future financial health. This strategic mix of product development and financial maneuvers positions Ascendis uniquely within the biotech landscape as it transitions towards profitability forecasted with an impressive annual earnings growth rate of 59.79%. Get an in-depth perspective on Ascendis Pharma's performance by reading our health report here. Explore historical data to track Ascendis Pharma's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Natera, Inc. is a diagnostics company that offers molecular testing services globally, with a market cap of approximately $20.01 billion. Operations: The company generates revenue primarily from the development and commercialization of molecular testing services, totaling approximately $1.70 billion. Natera, a player in the genetic testing and diagnostics sector, is steering through a dynamic phase marked by strategic board expansions and intriguing clinical trials. With a revenue leap to $1.87 billion forecasted for 2025, the company's financial trajectory reflects vigorous growth, notably outpacing broader market trends. Recent R&D initiatives like the HEROES trial underscore Natera's commitment to pioneering in oncological research, potentially reshaping therapeutic approaches in cancer care. Moreover, the adoption of its Signatera test for Medicare coverage marks a significant milestone, enhancing its standing in precision medicine and boosting its commercial prospects amidst competitive pressures. Unlock comprehensive insights into our analysis of Natera stock in this health report. Review our historical performance report to gain insights into Natera's's past performance. Embark on your investment journey to our 232 US High Growth Tech and AI Stocks selection here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:ALNY NasdaqGS:ASND and NasdaqGS:NTRA. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
03-03-2025
- Business
- Yahoo
Exploring US High Growth Tech Stocks In March 2025
Over the last 7 days, the United States market has experienced a slight decline of 1.3%, yet it has shown resilience with a 15% increase over the past year and earnings forecast to grow by 14% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to sustain growth amidst fluctuating market conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 25.26% 29.10% ★★★★★★ AsiaFIN Holdings 51.75% 82.69% ★★★★★★ Travere Therapeutics 28.43% 65.01% ★★★★★★ Alkami Technology 20.94% 85.17% ★★★★★★ AVITA Medical 27.78% 55.33% ★★★★★★ TG Therapeutics 29.48% 45.20% ★★★★★★ Clene 61.16% 59.11% ★★★★★★ Alnylam Pharmaceuticals 22.90% 58.64% ★★★★★★ Zai Lab 28.84% 67.49% ★★★★★★ Lumentum Holdings 21.24% 119.37% ★★★★★★ Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases, with a market cap of $2.23 billion. Operations: Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases. As a clinical-stage biopharmaceutical company, it is currently not generating revenue from its operations. Soleno Therapeutics, despite its recent financial challenges marked by a net loss of $175.85 million for the year, remains a focal point in biotech due to its aggressive R&D initiatives and anticipated revenue growth. The company's strategic maneuvers, including a significant shelf registration of $82.25 million and securing a $200 million loan for advancing Prader-Willi syndrome treatments, underscore its commitment to innovation and market expansion. With an expected annual revenue increase of 49.4%, Soleno is positioning itself strategically within the high-growth biotech sector, aiming to leverage R&D breakthroughs into commercial success in the coming years. Dive into the specifics of Soleno Therapeutics here with our thorough health report. Learn about Soleno Therapeutics' historical performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Ascendis Pharma A/S is a biopharmaceutical company that develops TransCon-based therapies for unmet medical needs across Denmark, Europe, North America, and internationally, with a market cap of $9.37 billion. Operations: Ascendis Pharma generates revenue primarily from its biotechnology segment, amounting to €363.64 million. The company's focus is on developing therapies using its proprietary TransCon technology platform. Ascendis Pharma has demonstrated resilience and strategic foresight in the high-growth biotech landscape, marked by a notable 32.5% annual revenue growth and a reduction in net loss from EUR 481.45 million to EUR 378.08 million year-over-year. The company's recent shelf registration of $108 million underscores its proactive approach to funding future innovations, while its R&D commitment is evident from the substantial advancements in its TransCon technology platforms, promising enhanced treatment efficacy across multiple therapeutic areas. Moreover, Ascendis' recent share repurchase program highlights confidence in its financial health and future prospects, positioning it as a dynamic player amidst challenging market conditions and ongoing patent disputes with competitors like BioMarin. Get an in-depth perspective on Ascendis Pharma's performance by reading our health report here. Gain insights into Ascendis Pharma's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: ServiceNow, Inc. offers cloud-based solutions for digital workflows across various regions globally and has a market capitalization of $191.53 billion. Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $10.98 billion. ServiceNow, a leader in digital workflow solutions, is capitalizing on the AI-driven transformation across industries. With a robust 15.2% annual revenue growth and an impressive 20.6% forecast in earnings growth, the company is setting benchmarks in integrating AI to enhance operational efficiencies. Recently, ServiceNow introduced AI agents for telecoms, developed with NVIDIA's cutting-edge technology, aimed at automating complex customer service and network operations workflows. This innovation not only underscores ServiceNow's commitment to R&D (spending significant portions of its $10.98 billion revenue on these initiatives) but also positions it strategically within a sector poised for substantial growth due to AI adoption. Click to explore a detailed breakdown of our findings in ServiceNow's health report. Assess ServiceNow's past performance with our detailed historical performance reports. Investigate our full lineup of 236 US High Growth Tech and AI Stocks right here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:SLNO NasdaqGS:ASND and NYSE:NOW. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
